Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Panbela Therapeutics Inc PBLA

Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is involved in enrolling patients in its randomized double-blind placebo-controlled clinical trial for the treatment of pancreatic cancer. The Company's lead assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X). Ivospemin is a polyamine analog designed to... see more

OTCQB:PBLA - Post Discussion

Panbela Therapeutics Inc > PBLA .... JMHO but this is how I see this Train Wreck
View:
Post by Iseneschal on Apr 26, 2023 11:51am

PBLA .... JMHO but this is how I see this Train Wreck

1.2 million shares o/s post RS on 01/12/23....then 7 million unit P.O at $2.25

The Maggot has been accumulating this post RS & P.O ever since 03/17/23

I'd say that this will be a big volume trader for a while

The Maggot will churn this ....big time because there's lots of people in this that want their money back

 Cheers !
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities